Search results for "arki"

showing 10 items of 1015 documents

Influence of Commensal Microbiota on the Enteric Nervous System and Its Role in Neurodegenerative Diseases

2017

When thinking about neurodegenerative diseases, the first symptoms that come to mind are loss of memory and learning capabilities, which all resemble hallmarks of manifestation of such diseases in the central nervous system (CNS). However, the gut comprises the largest nervous system outside the CNS that is autonomously active and in close interplay with its microbiota. Therefore, the enteric nervous system (ENS) might serve as an indicator of degenerative pathomechanisms that also affect the CNS. On the other hand, it might offer an entry point for devastating influences from the microbial community or – conversely – for therapeutic approaches via gut commensals. Within the last years, the…

0301 basic medicineNervous systemGastrointestinal DiseasesCentral nervous systemNeurodegenerative DiseasesParkinson DiseaseFecal Microbiota TransplantationBiologyGut florabiology.organism_classificationEnteric Nervous SystemGastrointestinal Microbiome03 medical and health sciencesNeuroprotective Agents030104 developmental biology0302 clinical medicinemedicine.anatomical_structureAlzheimer DiseasemedicineAnimalsHumansImmunology and AllergyEnteric nervous systemNeuroscience030217 neurology & neurosurgeryJournal of Innate Immunity
researchProduct

Transcriptomic and Genetic Associations between Alzheimer's Disease, Parkinson's Disease, and Cancer.

2021

Simple Summary Epidemiological studies have identified a link between neurodegenerative disorders and a reduced risk of overall cancer. Increases and decreases in the risk of site-specific cancers have also been reported. However, it is still unknown whether these associations arise due to shared genetic and molecular factors or are explained by other phenomena (e.g., biases in epidemiological studies or the use of medication). In this study, we aimed to investigate the potential molecular, genetic, and pharmacological links between Alzheimer’s and Parkinson’s diseases and a large panel of 22 cancer types. To examine the overlapping involvement of genes and pathways, we obtained differentia…

0301 basic medicineOncologyCancer ResearchParkinson's diseaseGenetic correlationsGenome-wide association studyDiseaseComorbidityParkinson Enfermedad de - Aspectos genéticos.chemistry.chemical_compound0302 clinical medicineExemestaneParkinson's disease - Genetic aspects.MedicineParkinsonCáncer - Aspectos genéticos.Càncer -- Aspectes genèticsRC254-282Alzheimer's disease - Genetic aspects.NeurodegenerationNeoplasms. Tumors. Oncology. Including cancer and carcinogensCódigo genético.comorbidityOncology:Informàtica::Aplicacions de la informàtica::Bioinformàtica [Àrees temàtiques de la UPC]medicine.medical_specialtyGenetic code.Alzheimer Enfermedad de - Aspectos genéticos.Article03 medical and health sciencesInternal medicineParkinson Malaltia dePI3K/AKT/mTOR pathwaygenetic correlationsCancer - Genetic aspects.business.industryCancertranscriptomicmedicine.diseaseComorbidityAlzheimer Malaltia d'030104 developmental biologychemistryTranscriptomicmeta-analysesMeta-analysesNeurodegenerative disordersAlzheimerGene expressionbusiness030217 neurology & neurosurgeryCancers
researchProduct

Standardized measurement of circulating vitamin D [25(OH)D] and its putative role as a serum biomarker in Alzheimer's disease and Parkinson's disease

2019

The current review provides an overview on the development of 25(OH)D measurement standardization tools over the last three decades and clarifies whether there is a role as a serum biomarker for vitamin D in neurological diseases. In the past, a lack of internationally recognized 25(OH)D reference measurement procedures and reference standard materials led to unstandardized serum total 25(OH)D results among research and clinical care laboratories. The vitamin D Standardization Program (VDSP) has been introduced in 2010 to address this problem, however, vitamin D External Quality Assessment Scheme (DEQAS) reports still show substantial sample- to- sample variability. Further, immunoassays, w…

0301 basic medicineOncologymedicine.medical_specialtyParkinson's diseaseParkinson's diseaseClinical BiochemistryDiseaseBiochemistry03 medical and health sciences0302 clinical medicineAlzheimer DiseaseTandem Mass SpectrometrySerum biomarkersInternal medicineExternal quality assessmentmedicineVitamin D and neurologyHumansIn patientVitamin D25(OH)Dbusiness.industryBiochemistry (medical)Parkinson DiseaseBiomarkerGeneral MedicineAlzheimer's diseasemedicine.diseaseStandardization030104 developmental biology030220 oncology & carcinogenesisBiomarker (medicine)Alzheimer's diseasebusinessBiomarkersChromatography LiquidHumanClinica Chimica Acta
researchProduct

An update on intracerebral stem cell grafts.

2018

Introduction: Primary neurological disorders are notoriously debilitating and deadly, and over the past four decades stem cell therapy has emerged as a promising treatment. Translation of stem cell therapies from the bench to the clinic requires a better understanding of delivery protocols, safety profile, and efficacy in each disease. Areas covered: In this review, benefits and risks of intracerebral stem cell transplantation are presented for consideration. Milestone discoveries in stem cell applications are reviewed to examine the efficacy and safety of intracerebral stem cell transplant therapy for disorders of the central nervous system and inform design of translatable protocols for c…

0301 basic medicineOncologymedicine.medical_specialtyParkinson's diseaseTraumatic brain injurymedicine.medical_treatmentmulti-system atrophyNeuroprotection03 medical and health sciencesGraft vs Host Reaction0302 clinical medicineHuntington's diseaseCentral Nervous System DiseasesRisk FactorsInternal medicineMedicineAnimalsHumansPharmacology (medical)amyotrophic lateral sclerosiAmyotrophic lateral sclerosisStem cellbusiness.industryGeneral NeuroscienceMultiple sclerosistraumatic brain injuryStem-cell therapymedicine.diseasestroke030104 developmental biologyBlood-Brain Barriermultiple sclerosiParkinson’s diseaseneuroprotectionNeurology (clinical)Stem cellbusiness030217 neurology & neurosurgeryHuntington’s diseaseStem Cell TransplantationExpert review of neurotherapeutics
researchProduct

Interference of carbidopa and other catechols with reactions catalyzed by peroxidases

2018

Abstract Background A number of compounds, including ascorbic acid, catecholamines, flavonoids, p-diphenols and hydrazine derivatives have been reported to interfere with peroxidase-based medical diagnostic tests (Trinder reaction) but the mechanisms of these effects have not been fully elucidated. Methods Reactions of bovine myeloperoxidase with o-dianisidine, bovine lactoperoxidase with ABTS and horseradish peroxidase with 4-aminoantipyrine/phenol in the presence of carbidopa, an anti-Parkinsonian drug, and other catechols, including l -dopa, were monitored spectrophotometrically and by measuring hydrogen peroxide consumption. Results Chromophore formation in all three enzyme/substrate sy…

0301 basic medicineParkinson's diseaseBiophysicsCatecholsperoxidaseBiochemistryHorseradish peroxidaseCatalysis03 medical and health scienceschemistry.chemical_compoundmedicineAnimalsHumansLactoperoxidasecarbidopaHydrogen peroxideenzymatic assay interferenceMolecular BiologyHorseradish PeroxidaseCatecholABTS030102 biochemistry & molecular biologybiologyMolecular StructureMonophenol MonooxygenaseLactoperoxidasehydrazineHydrogen PeroxidecatecholAscorbic acidCombinatorial chemistryMolecular Docking Simulation030104 developmental biologychemistryChromogenic CompoundsPeroxidasesCarbidopabiology.proteinParkinson’s diseaseCattleOxidation-Reductionmedicine.drugPeroxidaseBiochimica et Biophysica Acta-General Subjects
researchProduct

Alterations in White Matter Network and Microstructural Integrity Differentiate Parkinson’s Disease Patients and Healthy Subjects

2019

Parkinson’s disease (PD) is a neurodegenerative disease, neuropathologically characterized by progressive loss of neurons in distinct brain areas. We hypothesize that quantifiable network alterations are caused by neurodegeneration. The primary motivation of this study was to assess the specific network alterations in PD patients that are distinct but appear in conjunction with physiological aging. 178 subjects (130 females) stratified into PD patients, young, middle-aged and elderly healthy controls (age- and sex-matched with PD patients), were analyzed using 3D-T1 magnetization-prepared rapid gradient-echo (MPRAGE) and diffusion weighted images acquired in 3T MRI scanner. Diffusion modeli…

0301 basic medicineParkinson's diseaseCognitive NeuroscienceSpleniumCorpus callosumcomputer.software_genrelcsh:RC321-571White matterdiffusion MRI03 medical and health sciences0302 clinical medicineVoxelMedicinelcsh:Neurosciences. Biological psychiatry. NeuropsychiatryOriginal Researchbusiness.industryagingmedicine.diseasenetwork connectivity analysis030104 developmental biologymedicine.anatomical_structureCorticospinal tractParkinson’s diseasebusinessNeuroscienceInsulacomputerwhite matter030217 neurology & neurosurgeryNeuroscienceDiffusion MRIFrontiers in Aging Neuroscience
researchProduct

The Pharmacology of Visual Hallucinations in Synucleinopathies

2019

Visual hallucinations (VH) are commonly found in the course of synucleinopathies like Parkinson's disease and dementia with Lewy bodies. The incidence of VH in these conditions is so high that the absence of VH in the course of the disease should raise questions about the diagnosis. VH may take the form of early and simple phenomena or appear with late and complex presentations that include hallucinatory production and delusions. VH are an unmet treatment need. The review analyzes the past and recent hypotheses that are related to the underlying mechanisms of VH and then discusses their pharmacological modulation. Recent models for VH have been centered on the role played by the decoupling …

0301 basic medicineParkinson's diseaseParkinson's diseaseReviewPharmacologySerotonergicdefault mode network03 medical and health sciencesGlutamatergic0302 clinical medicineDopaminemedicinePharmacology (medical)Default mode networkPharmacologySynucleinopathiesDementia with Lewy bodiesbusiness.industrylcsh:RM1-950visual hallucinationmedicine.diseaselcsh:Therapeutics. Pharmacology030104 developmental biology030220 oncology & carcinogenesisCholinergicSettore MED/26 - Neurologiasynucleinopathydementia with Lewy bodiesbusinessmedicine.drugFrontiers in Pharmacology
researchProduct

Enhanced activity of glycolytic enzymes in Drosophila and human cell models of Parkinson's disease based on DJ-1 deficiency

2020

ABSTRACTParkinson’s disease (PD) is a neurodenerative debilitating disorder characterized by progressive disturbances in motor, autonomic and psychiatric functions. The pathological hallmark of PD is the loss of dopaminergic neurons in the substantia nigra pars compacta, which causes striatal dopamine deficiency. Although most PD cases are sporadic (iPD), approximately 5-10% of all patients suffer from monogenic PD forms caused by highly penetrant rare mutations segregating with the disease in families (fPD). One of the genes linked to monogenic PD is DJ-1. Mutations in DJ-1 cause autosomal recessive early-onset forms of fPD; however, it has been shown that an over-oxidized and inactive for…

0301 basic medicineParkinson's diseaseProtein CarbonylationProtein Deglycase DJ-1MutantNerve Tissue ProteinsSubstantia nigraBiologymedicine.disease_causeBiochemistryNeuroprotection03 medical and health sciences0302 clinical medicinePhysiology (medical)medicineAnimalsDrosophila ProteinsHumansGlycolysisGeneLoss functionPars compactaChemistryDopaminergicParkinson Diseasemedicine.diseasePhenotypeCell biologyOxidative Stress030104 developmental biologyDrosophilaGlycolysis030217 neurology & neurosurgeryOxidative stressFree Radical Biology and Medicine
researchProduct

Identification of potential therapeutic compounds for Parkinson's disease using Drosophila and human cell models.

2017

Abstract Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease. It is caused by a loss of dopaminergic neurons in the substantia nigra pars compacta, leading to a decrease in dopamine levels in the striatum and thus producing movement impairment. Major physiological causes of neurodegeneration in PD are oxidative stress (OS) and mitochondrial dysfunction; these pathophysiological changes can be caused by both genetic and environmental factors. Although most PD cases are sporadic, it has been shown that 5–10% of them are familial forms caused by mutations in certain genes. One of these genes is the DJ-1 oncogene, which is involved in an early…

0301 basic medicineParkinson's diseaseProtein Deglycase DJ-1Drug Evaluation PreclinicalSubstantia nigraNerve Tissue ProteinsBiologymedicine.disease_causeBiochemistryAnimals Genetically Modified03 medical and health sciences0302 clinical medicineDopaminePhysiology (medical)Cell Line TumorDrug DiscoverymedicineAnimalsDrosophila ProteinsHumansGeneticsMutationPars compactaNeurodegenerationDopaminergicParkinson Diseasemedicine.diseaseDisease Models AnimalOxidative Stress030104 developmental biologyGene Knockdown TechniquesMutationCancer researchDrosophila030217 neurology & neurosurgeryOxidative stressLocomotionmedicine.drugFree radical biologymedicine
researchProduct

Parkinson's disease: towards better preclinical models and personalized treatments.

2016

Non peer reviewed

0301 basic medicineParkinson's diseaseeducationMEDLINEBioinformatics03 medical and health sciencesCellular and Molecular Neuroscience0302 clinical medicineDEFICITSMedicineAnimalsHumansMolecular BiologyPharmacologybusiness.industryParkinson DiseaseCell Biologymedicine.diseaseMolecular medicine3. Good healthMICE030104 developmental biologyNeuroprotective AgentsCell Biology; Molecular Biology; Molecular Medicine; Pharmacology; Cellular and Molecular NeuroscienceMolecular Medicine3111 Biomedicinebusiness030217 neurology & neurosurgeryCellular and molecular life sciences : CMLS
researchProduct